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Abstract
De novo rare damaging variants in genes involved in critical developmental path-
ways, notably regulation of synaptic transmission, have emerged as a frequent cause
of neurodevelopmental disorders (NDD). NDD show great locus heterogeneity and
for many of the associated genes, there is substantial phenotypic diversity, including
epilepsy, intellectual disability, autism spectrum disorder, movement disorders, and
combinations thereof. We report two unrelated patients, a young girl with early‐
onset refractory epilepsy, severe disability, and progressive cerebral and cerebellar
atrophy, and a second girl with mild dysmorphism, global developmental delay, and
moderate intellectual disability in whom trio‐based whole‐exome sequencing ana-
lysis uncovered de novo missense variants in CHRM1. Biochemical analyses of one
of the NDD‐associated variants proved that it caused a reduction in protein levels
and impaired cellular trafficking. In addition, the mutated receptor showed defec-
tive activation of intracellular signaling pathways. Our data strengthen the concept
that brain‐reduced muscarinic signaling lowers the seizure threshold and severely
impairs neurodevelopment.
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Developmental and epileptic encephalopathies (DEE), are a group of
diseases with onset within the first year of life where developmental
impairment is recognized to occur as a direct consequence of the genetic
mutation, in addition to the potential deleterious effect of epileptic ac-
tivity on brain development (Scheffer et al., 2017). With the transition of
next‐generation sequencing to genetic diagnostics, the pace of DEE gene
discovery has accelerated with over 100 currently known genetic etiol-
ogies (Brunklaus et al., 2020). Importantly, the genes underlying DEE are
known to often cause a range of neurodevelopmental disorders (NDD)
with or without epilepsy. Most of these genes encode proteins related to
one of six fundamental processes: Ion transport, cell growth and differ-
entiation, regulation of synaptic processes, transport and metabolism of
small molecules within and between cells, and regulation of gene tran-
scription and translation (Symonds & McTague, 2020).
Cholinergic signaling has been associated with the maintenance
of cortical network excitability balance (Drever et al., 2011). To date,
only mutations in the nicotinic acetylcholine receptor have been
reported as disease‐causing in genetic epilepsies (Steinlein et al.,
1995). However, mutations affecting PLCB1, encoding phospholipase
C isoform β1, which is placed downstream on the muscarinic choli-
nergic signaling pathway, have been associated with a DEE pheno-
type (Kurian et al., 2010) and so are mutations in the subunits of the
CHRM1‐regulated Kv7 channels (Jentsch, 2000).
In the present study, we identify two patients with point muta-
tions in CHRM1, providing novel insight into the molecular me-
chanisms underlying DEE and neurodevelopmental impairment and
further implicate defects in the cholinergic pathway in severe in-
fantile epilepsies. Methods are described in the Supplementary sec-
tion. The study was approved by the local Ethics Committee (PR(AG)
223/2017) and informed consent was obtained from the patient's
parents according to the Helsinki declaration.
Case 1. The proband is a 10‐year‐old girl with epilepsy and severe
encephalopathy. She was born at term to healthy, unrelated parents after
uneventful pregnancy and delivery. After birth, she was noted to be
hypotonic, irritable, and difficult to feed. At age 1.5 months, she
developed tonic seizures featuring right arm extension and head version.
The reported physical exam showed no dysmorphic features or
organomegaly, absent visual fixation, and global hypotonia.
Electroencephalography (EEG) revealed multifocal epileptiform
discharges and diffuse background slowing. Brain MRI (magnetic
resonance imaging) (Figure 1a), array CGH, serum lactate, amino acids,
sialotransferrin pattern, very‐long‐chain fatty acids, and biotinidase, urine
organic acids, CSF folate, purines, neurotransmitter metabolites, and
CSF/plasma glucose ratio were normal. Seizures persisted daily despite
treatment with pyridoxine, phenobarbital, sodium valproate, or
carbamazepine, and by age 4 months, manifested as a combination of
tonic spasms, myoclonic jerks, and dysautonomic signs. At age 2 years 11
months, she displayed microcephaly with HC: 44.5 cm (−3 SD), right
occipital plagiocephaly, and poor contact despite brief visual fixation and
smiling in reaction to voice; other findings were horizonto‐rotatory
nystagmus, spastic quadriparesis, hyperreflexia, extensor plantar
responses, and occasional axial or segmental myoclonia. The patient
suffered on average two to three seizures per day, mostly generalized
tonic, heralded by a flexor spasm and accompanied by oral automatisms
and eyelid myoclonia, each lasting 1–5min. EEG revealed a high‐voltage
background with multifocal spikes of occipitotemporal predominance.
Seizures proved refractory to treatment with different combinations of
topiramate, lamotrigine, gabapentin, clobazam, levetiracetam, lacosamide,
and eslicarbacepine acetate. A repeat MRI at age 4 years showed mild
enlargement of subarachnoidal spaces, a relatively thick corpus callosum,
and marked cerebellar atrophy with vermian predominance (Figure 1a).
Magnetic resonance spectroscopy showed the presence of a creatine
peak. She currently remains wheelchair‐bound, with little awareness of
her surroundings (Figure 1c). Seizure frequency has been reduced to a
few per week while on perampanel monotherapy.
Whole‐exome sequencing (WES) detected the NM_0
00738.2:c.1139C>T; p.(Pro380Leu) de novo variant in the CHRM1 gene,
encoding the muscarinic acetylcholine receptor 1 (Figure 1d). This variant
modifies a highly conserved residue in the orthologous and paralogous
receptors. The p.Pro380Leu variant is considered as damaging or po-
tentially disease‐causing by various in silico predictors and is not present
in general population databases. Therefore, the p.Pro380Leu variant is
considered likely pathogenic. In the recently solved three‐dimensional
structure of CHRM1 (Maeda et al., 2019), residue Pro380 determines a
kink in the C terminal part of helix 6 (Figure 1e).
No additional CHRM1 variants were found by WES reanalysis in
a cohort of over 102 patients with DEE. However, a match was
detected upon sharing the novel variant in the Matchmaker
Exchange platform (Case 2).
Case 2. This is a 14‐year‐old girl born at 28 weeks gestation to
healthy, unrelated parents. Birth weight was 860 g, length 34 cm, and
head circumference 24 cm. Despite prematurity, the neonatal period
was relatively uneventful, did not require ventilation and serial cerebral
ultrasounds were all normal. She showed some dysmorphic features
including right hemifacial microsomia, congenital torticollis with
plagiocephaly, high‐arched palate, hypertelorism, and bilateral fifth
finger clinodactyly. She was hypotonic early on and displayed feeding
difficulties and axial titubation. Psychomotor development was globally
delayed. She sat unassisted at age 2 years and walked after age 3 years.
On follow‐up, she displayed general motor clumsiness, crouch gait, right
esotropia, very limited language with right‐sided sensorineural
hypoacusia, and poor social skills. Chromosomal analysis excluded
22q.11 deletion syndrome and the metabolic screen was normal. Brain
MRI at age 5 (Figure 1b) showed mild ventriculomegaly, small pons, and
cerebellar peduncles, and a small and detached cerebellar vermis. She
has developed severe scoliosis, which required surgical intervention. No
seizures have been recorded. Current examination reveals global
cognitive dysfunction, with reduced and abnormal speech and
additional oromotor difficulties. Eye movements are full and no
nystagmus is appreciated. Fine motor skills are deficient with no
pareses or pyramidal signs. She currently attends a special school and is
able to recognize letters but unable to read; she appears withdrawn
with frequent bouts of obsessive or aggressive behaviors. Her head
circumference is 49 cm (−4 SD).
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WES detected the NM_000738.2:c.1274T>C;p.(Phe425Ser) de novo
variant in CHRM1 (Figure 1d). Phe425 is located at the segment H8
(Maeda et al., 2019) located close to the cytoplasmic side and it is also
very conserved in all CHRM homologs. See Table S1 for a comparative
summary of clinical and genetic features of Cases 1 and 2.
We focused on the mutation p.(Pro380Leu) as the patient with
this mutation is more severely affected. Thus, wild‐type (WT)
CHRM1 and mutant were expressed into HEK293T cells and protein
expression levels were analyzed (Figure 2a). The mutant showed a
different protein pattern band compared to WT protein, with a re-
duction of protein band 1 (WT: 71% ± 14%, P380L: 14% ± 2% of total
protein, n = 5), corresponding to the mature glycosylated form, and
an increase of bands 2 and 3 (WT: 19% ± 10%, P380L: 64% ± 26% of
total protein, n = 5), corresponding to immature forms, as revealed by
glycosidase treatment (not shown). Then, we reasoned that mutation
P380L impairs the correct maturation of CHRM1 protein.
To verify this biochemical data, we cotransfected HeLa cells with
WT CHRM1 or mutant plus PH‐GFP (green fluorescent protein), a
fluorescent probe that labels the plasma membrane (Figure 2b). Al-
though WT CHRM1 was detected mainly at the plasma membrane,
predominantly colocalizing with PH‐GFP (yellow staining) (Pearson's
correlation coefficient: Rr = .8 ± .02, n=3/65 cells), the mutant was
F IGURE 1 Identification of de novo mutations in CHRM1 in patients with a developmental disorder or epileptic and developmental
encephalopathy. (a) Case 1 brain MRI at age 1 year (top) and 4 years (bottom) showed right occipital plagiocephaly, mild enlargement of
subarachnoidal spaces, a relatively thick corpus callosum, and marked cerebellar atrophy with vermian predominance (arrows). (b) In Case 2,
MRI at age 5 years revealed prominent pontine (asterisks) and mild vermian hypoplasia. Note mild enlargement of the lateral ventricles. (c) Case
1 at age 8 years, exhibiting poor eye contact, hypotonia, and quadriparesis. (d) Pedigrees of both probands, showing the p.(Pro380Leu)
heterozygous carrier (filled symbol), and her unaffected parents and half‐sister and the p.(Phe425Ser) heterozygous carrier (filled symbol) and
her unaffected parents. (e) 3D CHRM1 protein structure model shows the seven transmembrane helixes (in red) and the position of Proline 380
(in pink), which determines a kink in the distal part of helix 6 and Phe425 (in blue), located close to the G11 binding site. 3D, three‐dimensional;
MRI, magnetic resonance imaging
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almost exclusively detected in intracellular compartments (Figure 2b),
showing less degree of colocalization with PH‐GFP (Rr = .3 ± .02, n=3/45
cells). Thus, immunofluorescence studies confirmed that the mutation
reduced the surface expression of the CHRM1 protein.
Muscarinic acetylcholine receptors are involved in signaling
pathways related to adenosine 3ʹ,5ʹ‐cyclic monophosphate (cAMP)
and calcium intracellular release. CHRM1 is mainly known to signal
through Gq/11‐activating phospholipase C that increases IP3
calcium‐related pathways. However, cAMP signaling has also been
associated with CHRM1. Reporter assays were performed in
HEK293T cells to detect cAMP‐ (Figure 2c) or IP3/Ca2+‐associated
transcription (Figure 2d). Both reporters displayed a reduced sig-
naling activation for the mutant compared with WT.
In our first patient, seizure onset was in early infancy, yet she dis-
played neurological and behavioral abnormalities since birth and hence
the label DEE. Severely impaired cognitive and motor development was
already notable within the first year of life and acquired microcephaly
reflected atrophy and/or cerebral underdevelopment in the context of an
F IGURE 2 The mutation p.P380L causes a trafficking and a functional defect to the CHRM1 protein. (a) Western blot analysis of
transfected cells with Flag‐tagged CHRM1 WT or carrying p.(Pro380Leu) mutation was performed with an antibody detecting the flag epitope.
CHRM1 is a protein whose molecular weight is 52 kDa, but the mature protein increases its molecular weight due to glycosylation. Different
protein band pattern was obtained corresponding to (1) mature glycosylated protein form, (2) and (3) immature forms. Cells transfected with
the mutant showed an increase in forms 2 and 3 and a decrease in mature glycosylated CHRM1 compared to cells transfected with WT. β‐Actin
was used to normalize protein levels. Statistics were performed from five independent experiments. (b) HeLa cells cotransfected with WT or
mutant CHRM1 and PH‐GFP, were studied by immunofluorescence. Co‐localization between CHRM1 (red label) and PH‐GFP (green label) was
analyzed (Merge) by Pearson´s correlation analysis. Statistics were performed from 3 independent experiments. (c, d) Signaling pathways
associated to CHRM1 were studied by a luciferase signal assay in HEK293T cells transfected with WT or mutant CHRM1, after treatment with
Carbachol, a CHRM1 agonist. (c) cAMP signaling pathway activation was studied through a CRE gene reporter. Negative controls and forskolin‐
treated cells (positive control) were used to normalize results. (d) IP3‐Ca2+ signaling pathway activation was studied through an NFAT gene
reporter. Negative controls and Ca+ PMA (phorbol myristate acetate)‐treated cells (as a positive control) were used to normalize results.
Statistics were performed from three independent experiments. cAMP, adenosine 3ʹ,5ʹ‐cyclic monophosphate; GFP, green fluorescent protein;
WT, wild‐type
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epileptic and developmental disorder. Our second patient had early‐
onset cognitive and motor impairment as well, but her phenotype is
better covered under the more unspecific label of NDD. De novo mu-
tations in variance‐intolerant genes are a well‐known cause of NDD,
including DEE. In fact, patients with developmental disorders resulting
from mutations in novel genes, as opposed to many classical conditions,
are often phenotypically dissimilar and phenotype‐driven recognition of
these genetic defects is revealing rather unlikely (Kaplanis et al., 2020). In
keeping, we have previously reported wide phenotype variability, from
epileptic encephalopathy to NDD and autism spectrum disorder, in as-
sociation with variants in other synaptic genes such as VAMP2 or GRIA2
(Salpietro, Dixon, et al., 2019; Salpietro, Malintan, et al., 2019).
Our findings hint at CHRM1 dysfunction as a possible novel cause of
NDD. Additional evidence may come from the recent finding of a mis-
sense CHRM1 variant in a young boy included in an autism spectrum
disorder cohort sequencing study (Satterstrom et al., 2020). Thus, a total
of three putative pathogenic CHRM1 variants have been associated with
neurodevelopmental phenotypes and all of them are assessed as disease‐
causing by main in silico predictors (Table S1). It is also the first instance
where the metabotropic muscarinic receptors are linked to an epileptic
disorder. Admittedly, this is based only on the fact that we have identi-
fied one de novo mutation in a single patient. However, we believe that
this mutation is pathogenic as it affects a conserved residue in all CHRM
proteins that is present in an important structural element of the
transmembrane segment 6 (TM6). The TM6 suffers a small rotation and
an outward displacement during receptor activation that allows the G
protein to engage the receptor core (Maeda et al., 2019). Mutation
p.(Phe425Ser) may also partially destabilize the binding of the G11
protein, as it is very close to the residues cysteine 421 and asparagine
422, which have been involved in the binding of the G protein. Thus, it
could be that both mutations impair receptor activation. In addition,
expression of the Pro380Leu mutant protein in transfected cells at the
membrane is reduced possibly due to a folding defect. We reasoned that,
based on the fact that this mutant is expressed at low levels, it is very
difficult to consider that the mutant protein may exert a dominant‐
negative effect. Rather, we support the hypothesis that the patient may
suffer a reduction of cholinergic activity due to haploinsufficiency. This
hypothesis is in agreement with the fact that a minor reduction of KCNQ
activity, a known target of muscarinic regulation, is enough to cause an
epileptic phenotype (Jentsch, 2000).
How a reduction in cholinergic activity in humans may lead to
an early epileptic or developmental phenotype? One of the best‐
known targets of muscarinic regulation is the M current formed
by KCNQ channels through Gq/11 mediated protein signals that
increase phospholipase C‐beta activity, which results in con-
sumption of phosphatidylinositol 4,5‐bisphosphate (PIP2) re-
sulting in KCNQ inhibition. In this pathway, loss of function
mutations in KCNQ channels or PLCB1 cause epileptic en-
cephalopathy (Schoonjans et al., 2016). Thus, considering this
well‐known pathway, one simple hypothesis is that muscarinic
inhibition might result in increased KCNQ activity, which may
affect neuronal excitability properties. However, gain‐of‐
function variants in KCNQ2 do not show epileptic seizures
(Miceli et al., 2015). Thus, modulation of M current by CHRM1‐
PLCB1 might not be the only acting pathogenic mechanism.
CHRM1 might regulate many different targets including other ion
channels depending on the developmental stage and in a cell‐specific
manner. It is noteworthy that, although CHRM1 is nearly not expressed
in the cerebellum (Bakker et al., 2015), our patient 1 developed promi-
nent cerebellar atrophy suggesting that a defective CHRM1‐mediated
cholinergic activity may have resulted particularly damaging for Purkinje
cells. Patient 2 had also cerebellar vermian and pontine atrophy, while
her moderate ventricular enlargement could conceivably relate to white
matter injury in association with encephalopathy of prematurity.
In summary, our work further suggests that muscarinic activity
in the brain might affect multiple processes regulating seizure sus-
ceptibility and neuronal development and therefore, CHRM1 can be
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